In Brief: Datascope/Masimo
This article was originally published in The Gray Sheet
Datascope/Masimo: Enter product development and licensing agreement under which Datascope will incorporate Mission Viejo, California-based Masimo's pulse oximetry signal processing and sensor technology into its patient monitoring systems. Masimo's technology is designed to "measure weak physiological signals even in the presence of high levels of interfering signals or motion artifact," the company says. Datascope says the technology will aid in the monitoring of "patients in low perfusion states and during periods of motion"...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.